Recent research highlights the mTOR signaling pathway as a key therapeutic target for ocular diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma, and others. These diseases share common features like oxidative stress, which damages critical retinal cells (photoreceptors, retinal ganglion cells, and retinal pigment epithelium). The mTOR pathway regulates oxidative stress but is also affected by reactive oxygen species (ROS), making its study crucial for developing new treatments.
This book explores further mTOR-mediated autophagy in disease progression and focuses on rapamycin (an mTOR inhibitor) as a potential therapy for various eye conditions, including myopia, Graves ophthalmopathy, dry eye, uveitis, Sjögren’s syndrome, geographic atrophy, and ocular tumors. By compiling key findings from basic and clinical research, the book provides a comprehensive overview of mTOR's role in ocular diseases, serving as an essential resource for researchers, clinicians, students, and industry professionals in ophthalmology.
The work also discusses mTORC1 inhibition as a strategy to slow myopia progression and examines rapamycin’s broader applications, offering insights into future clinical advancements.
AVAILABLE FROM:
Amazon
Springer
Kambiz Thomas Moazed, MD
After graduation from medical school, he completed a year of research fellowship in eye pathology at the department of Ophthalmology at Stanford University Hospital in California.
Under direction of Dr. Peter Egbert. He then completed a year of residency in General surgery at Stanford University, at Stanford medical center in California.
He then followed his interest in ophthalmology and completed another year of fellowship in eye pathology at Harvard medical school department of ophthalmology at Massachusetts Eye and Ear Infirmary Under direction of Dr. Daniel Albert. He then completed the ophthalmology residency program at the Harvard University at Massachusetts Eye and Ear Infirmary and was graduated in 1982. Dr. Moazed has received his Board certification from the American Board of Ophthalmology in 1983.He then completed a year of fellowship in ophthalmic plastic surgery, orbital surgery and lacrimal duct surgery at Edward Harkness Eye Institute at Columbia University under the direction of Dr. Stanley C. Cooper. Then he became affiliated with Columbia University in New York City and became associate clinical professor at Columbia University and was in charge of teaching residents in eye pathology and ophthalmic surgery at St. Luke's Roosevelt Hospital centers in New York for 25 years. At the same time period he became the director of oculo-plastic surgery and orbital surgery at Harlem Hospital under affiliation to Columbia University for 15 years.
He has received a patent for his invention of the laser tear duct probe and tear duct insert, and has been one of the pioneers in introducing laser assisted Lacrimal duct surgery for tear duct obstruction. He has received another patent on eye color modification of the iris and currently working on 3 other patents on the latest approaches to modify human eye color. He started to collect all the knowledge that he has collected in the past 35 years in a book that is titled "The Iris, Understanding the Essentials" The book which was published by Springer Publishing company in August 2020. His second book "Quantum Biology of the Eye, Understanding the Essentials" which explores the merge of quantum physics with Biology was published in 2023 and his third book "Quest for Eye Color Modification" which was published in 2024.
Dr. Moazed has over 40 years of surgical experience in NYC. At present he is an active surgical attending at Manhattan Eye and Ear and Throat Hospital and at Mount Sinai Roosevelt/St. Luke's Hospitals.
ABOUT THE AUTHOR
